• Explore /
  • Poster
  • / Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.

Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.

Abstract Video & Slides Poster

Authors

null

Alison R. Sehgal

University of Pittsburgh Medical Center, Pittsburgh, PA

Alison R. Sehgal , Gerhard Hildebrandt , Nilanjan Ghosh , John E. Godwin , Nina D. Wagner-Johnston , Daanish Hoda , Edward J. Licitra , Javier Munoz , Nikolaus S. Trede , Lei Wang , Jerill Thorpe , Leo I. Gordon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03483103

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8040)

DOI

10.1200/JCO.2020.38.15_suppl.8040

Abstract #

8040

Poster Bd #

373

Abstract Disclosures

Similar Posters

First Author: Alison Sehgal

First Author: Sarah Marie Larson

First Author: Larry D. Anderson, Jr

First Author: Jeremy S. Abramson